Grace Therapeutics
(NASDAQ) GRCE
Grace Therapeutics Financials at a Glance
Market Cap
$36.83M
Revenue (TTM)
$0.00
Net Income (TTM)
-$9.49M
EPS (TTM)
-$0.48
P/E Ratio
-6.60
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$2.38
Volume
280,313.221
Open
$2.22
Price
$2.38
Volume
280,313.221
Open
$2.22
Previous Close
$2.38
Daily Range
$2.21 - $2.38
52-Week Range
$1.79 - $5.18
Estimated Earnings Date
Jun 23, 2026
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$2.38
Volume
280,313.221
Open
$2.22
Previous Close
$2.38
Daily Range
$2.21 - $2.38
52-Week Range
$1.79 - $5.18
Estimated Earnings Date
Jun 23, 2026
GRCE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Grace Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
5
CEO
Prashant Kohli, MBA
Website
www.gracetx.comHeadquarters
Princeton, NJ 08540, US
GRCE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-12%
Return on Capital
-26%
Return on Assets
-14%
Earnings Yield
-15.15%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$36.83M
Shares Outstanding
15.47M
Volume
280.31K
Avg. Volume
726.32K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$0.00
EBITDA
$0.00
Operating Cash Flow
-$8.87M
Capital Expenditure
$0.00
Free Cash Flow
-$8.87M
Cash & ST Invst.
$16.98M
Total Debt
$0.00
Grace Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$36.83M
N/A
Market Cap/Employee
$9.21M
N/A
Employees
4
N/A
Net Income
-$427.78K
-147.2%
EBITDA
-$5.62M
-24.0%
Quarterly Fundamentals
Total Cash
$16.98M
-23.3%
Total Debt
$0.00
N/A
Accounts Receivable
$20.00K
-84.1%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-14.24%
N/A
Return on Invested Capital
-25.91%
N/A
Free Cash Flow
-$1.71M
+42.2%
Operating Cash Flow
-$1.71M
+42.2%
